Implication of VEGFR2 in systemic lupus erythematosus: A combined genetic and structural biological approach

Clinical and Experimental Rheumatology

Volumn 31, Issue 1, 2013, Pages 97-102

  Vazgiourakis, Vassillis M ^a   Zervou, Maria I ^a   Eliopoulos, Elias ^b   Sharma, Shruti ^c   Sidiropoulos, Prodromos ^d   Franek, Beverly S ^c   Myrthianou, Effie ^a   Melissourgaki, Maria ^d   Niewold, Timothy B ^c   Boumpas, Dimitrios T ^a,d,e   Goulielmos, George N ^a  

^a UNIVERSITY OF CRETE   (Greece)

^b AGRICULTURAL UNIVERSITY OF ATHENS   (Greece)

^c UNIVERSITY OF CHICAGO   (United States)

^d UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

^e INSTITUTE OF MOLECULAR BIOLOGY AND BIOTECHNOLOGY   (Greece)

Author keywords

Association study; Gene polymorphisms; Systemic lupus erythematosus; Three Dimensional (3d) Model

Indexed keywords

GLUTAMINE; HISTIDINE; IMMUNOGLOBULIN; VALINE; VASCULOTROPIN RECEPTOR 2;

ADULT; AFRICAN AMERICAN; ARTICLE; AUTOPHOSPHORYLATION; CONTROLLED STUDY; ENDOTHELIUM CELL; ETHNICITY; EUROPEAN AMERICAN; FEMALE; GENE EXPRESSION REGULATION; GENE FREQUENCY; GENE FUNCTION; GENE LOCATION; GENE LOCUS; GENE STRUCTURE; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENOTYPE; GREECE; HISPANIC; HUMAN; INTRACELLULAR SIGNALING; MAJOR CLINICAL STUDY; MALE; MOLECULAR PATHOLOGY; PRIORITY JOURNAL; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM; SYSTEMIC LUPUS ERYTHEMATOSUS; VASCULOTROPIN RECEPTOR 2 GENE;

ADULT; CASE-CONTROL STUDIES; CHI-SQUARE DISTRIBUTION; ENDOTHELIAL CELLS; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GREECE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; MODELS, MOLECULAR; ODDS RATIO; PHENOTYPE; PHOSPHORYLATION; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTEIN CONFORMATION; RISK FACTORS; SIGNAL TRANSDUCTION; STRUCTURE-ACTIVITY RELATIONSHIP; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 84874865773     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. FOLKMAN J Antiangiogenesis in cancer therapy-endostatin and its mechanisms of action. Exp Cell Res 2006; 312: 594-607.
2. MARUOTTI N, CANTATORE FP, CRIVELLATO E, VACCA A, RIBATTI D Angiogenesis in rheumatoid arthritis. Histol Histopathol 2006; 21: 557-66.
3. WILKINSON-BERKA JL Vasoactive factors and diabetic retinopathy: vascular endothelial growth factor, cycoloxygenase-2 and nitric oxide. Curr Pharm Des 2004; 10: 3331-48.
4. ROSKOSKI RJR Vascular endothelial growth factor (VEGF) signaling during tumor progression, Crit Rev Oncol Hematol 2007; 62: 179-213.
5. RICCIERI V, STEFANANTONI K, VASILE M et al. Abnormal plasma levels of different angiogenic molecules are associated with different clinical manifestations in patients with systemic sclerosis. Clin Exp Rheumatol 2011; 29: S46-52.
6. FERRARA N, GERBER HP, LE COUTER J The biology of VEGF and its receptors. Nat Med 2003; 9: 669-76.
7. SCHLESSINGER J Cell signaling by receptor tyrosine kinases. Cell 2000; 103: 211-25.
8. STUTTFELD E, BALLMER-HOFER K Structure and function of VEGF receptors. IUBMB Life 2009; 61: 915-22.
9. FERRARA N Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 2004; 25: 581-611.
10. RUCH C, SKINIOTIS G, STEINMETZ MO, WALZ, T, BALLMER-HOFER K Structure of a VEGF-VEGF receptor complex determined by electron microscopy. Nat Struct Mol Biol 2004; 14: 249-50.
11. GRISANTI S, TATAR O The role of vascular endothelial growth factor and other endogenous interplayers in age-related macular degeneration. Prog Retin Eye Res 2008; 27: 372-90.
12. ZENG H, DVORAK HF, MUCHOPADHYAY D Vascular permeability factor (VPF)/vascular endothelial growth factor (VEGFR-1) modulates mitogenic activity of VEGFR-2 in endothelial cells. J Biol Chem 2000; 159: 993-1008.
13. SHIBUYA M Vascular endothelial growth factor receptor family genes: when did the three genes phylogenetically segregate? Biol Chem 2002; 383: 1573-9.
14. ROSKOSKI RJR: SUNITINIB a VEGF and PDGF receptor protein kinase and angiogenesis inhibitor. Biochem Biophys Res Commun 2007; 356: 323-8.
15. WANG Y, ZHEN Y, ZHANG W et al. J Am College Cardiol 2007; 50: 760-7.
16. TAN EM, COHEN AS, FRIES JF et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271-7.
17. LEPPANEN VM, PROTA AE, JELTSCH M et al. Structural determinants of growth factor binding and specificity by VEGF receptor 2. Proc Natl Acad Sci USA 2010; 107: 2425-30.
18. NOTREDAME C, HIGGINS DG, HERINGA J T-Coffee: A novel method for multiple sequence alignments. J Mol Biol 2000; 302: 205-17.
19. SALI A, BLUNDELL TL Comparative protein modeling by satisfaction of spatial restraints. J Mol Biol 1993; 234: 779-815.
20. YANG Y, XIE P, OPATOWSKY Y, SCHLESSINGER J Direct contacts between extracellular membrane proximal domains are required for VEGF receptor activation and cell signaling. Proc Natl Acad Sci USA 2010; 107: 1906-11.
21. YUZAWA S, OPATOWSKY Y, ZHANG Z, MANDIYAN V, LAX I, SCHLESSINGER J Structural basis for activation of the receptor tyrosine kinase KIT by stem cell factor. Cell 2007; 130: 323-34.
22. BROOKS BR, BRUCCOLERI RE, OLAFSON BD, STATES DJ, SWAMINATHAN S, KARPLUS M: CHARMM A program for macromolecular energy, minimization, and dynamics calculations. J Comput Chem 1983; 4: 187-217.
23. THE INTERNATIONAL HAPMAP CONSORTIUM The International HapMap Project. Nature 2003; 426: 789-96.
24. ISNER JM, ASAHARA T Angiogenesis and vasculogenesis as therapeutic strategies for postnatal neovascularization. J Clin Invest 1999; 103:1231-6.
25. WILHELM S, CARTER C, LYNCH M et al. Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat Rev Drug Discov 2006; 5: 835-44.
26. DELANO WL The PyMOL Molecular Graphics System on World Wide Web (2004); http://www.pymol.org.